SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) (the Company; bluebird) today announced updates to be presented at the 42 nd Annual J.P. Morgan Healthcare conference including ...
bluebird bio (NASDAQ:BLUE) traded lower for the fourth straight session as Bank of America and J.P. Morgan downgraded the gene therapy developer after its Q3 2024 results fell short of expectations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results